LLY

1,030.06

+0.68%↑

JNJ

243.75

+1.91%↑

ABBV

224.33

+1.19%↑

NVS

160.78

+0.8%↑

MRK

120.94

+2.06%↑

LLY

1,030.06

+0.68%↑

JNJ

243.75

+1.91%↑

ABBV

224.33

+1.19%↑

NVS

160.78

+0.8%↑

MRK

120.94

+2.06%↑

LLY

1,030.06

+0.68%↑

JNJ

243.75

+1.91%↑

ABBV

224.33

+1.19%↑

NVS

160.78

+0.8%↑

MRK

120.94

+2.06%↑

LLY

1,030.06

+0.68%↑

JNJ

243.75

+1.91%↑

ABBV

224.33

+1.19%↑

NVS

160.78

+0.8%↑

MRK

120.94

+2.06%↑

LLY

1,030.06

+0.68%↑

JNJ

243.75

+1.91%↑

ABBV

224.33

+1.19%↑

NVS

160.78

+0.8%↑

MRK

120.94

+2.06%↑

Kodu・Aktsiate loetelu・Gossamer Bio Inc

Gossamer Bio Inc

Avatud

SektorTervishoid

2.3

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.27

Max

2.36

Põhinäitajad
By Trading Economics
Sissetulek	-9.9M -48M
Müük	1.8M 13M
Kasumimarginaal	-362.728
Töötajad	144
EBITDA	-10M -45M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+401.33% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	11. märts 2026

Turustatistika
By TradingEconomics
Turukapital	-24M 523M
Eelmine avamishind	2.3
Eelmine sulgemishind	2.3

Uudiste sentiment

By Acuity

25%

75%

44 / 352 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

1.06 / 1.23 Toetus ja vastupanu

Gossamer Bio Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

11. veebr 2026, 23:47 UTC

Kuumad aktsiad

Stocks to Watch: AppLovin, Cisco, Cognex, Pilgrim's Pride

11. veebr 2026, 22:59 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Grab Holdings to Buy U.S.-Based Stash Financial

11. veebr 2026, 23:54 UTC

Tulu

McDonald's Says Its Value Campaign Is Paying Off -- 2nd Update

11. veebr 2026, 23:50 UTC

Market Talk

Global Equities Roundup: Market Talk

11. veebr 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for Takaichi's Economic Steps -- Market Talk

11. veebr 2026, 23:49 UTC

Tulu

Singtel: Key Focus Areas Are Strengthening Core Businesses, Scaling Growth Engines, Building Momentum Across Regional Associates >Z74.SG

11. veebr 2026, 23:45 UTC

Tulu

Singtel: Net Exceptional Gain of S$1.15B in 3Q Primarily From Sale of Partial Stake in Bharti Airtel>Z74.SG

11. veebr 2026, 23:42 UTC

Tulu

Singtel 3Q Underlying Net Profit S$744M Vs. S$680M >Z74.SG

11. veebr 2026, 23:41 UTC

Tulu

Singtel 3Q Net S$1.89B Vs. Net S$1.32B >Z74.SG

11. veebr 2026, 23:40 UTC

Tulu

Singtel 3Q Operating Revenue S$3.66B Vs. S$3.63B >Z74.SG

11. veebr 2026, 23:35 UTC

Market Talk

Gold Falls on Prospects of Long Fed Pause -- Market Talk

11. veebr 2026, 23:18 UTC

Market Talk

AppLovin CEO Looks to Soothe Concerns Over AI, Competition -- Market Talk

11. veebr 2026, 23:14 UTC

Market Talk

RBA Governor Faces Barrage of Questions About Govt Spending -- Market Talk

11. veebr 2026, 22:59 UTC

Tulu

Kakao 2025 Net KRW525.72B Vs. Loss KRW161.87B >035720.SE

11. veebr 2026, 22:59 UTC

Tulu

Kakao 2025 Oper Pft KRW732.04B Vs. Pft KRW460.21B >035720.SE

11. veebr 2026, 22:59 UTC

Tulu

Kakao 2025 Rev KRW8.099T Vs. KRW7.872T >035720.SE

11. veebr 2026, 22:58 UTC

Tulu

Kakao 4Q Net Loss Missed FactSet-Compiled Consensus

11. veebr 2026, 22:57 UTC

Tulu

Kakao 4Q Loss KRW39.30B Vs. Loss KRW395.21B >035720.SE

11. veebr 2026, 22:54 UTC

Tulu

Kakao 4Q Oper Pft KRW203.45B Vs. Pft KRW75.43B >035720.SE

11. veebr 2026, 22:53 UTC

Tulu

Kakao 4Q Rev KRW2.133T Vs. KRW1.957T >035720.SE

11. veebr 2026, 22:47 UTC

Tulu

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

11. veebr 2026, 22:47 UTC

Tulu

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

11. veebr 2026, 22:23 UTC

Tulu

Grab Holdings Expects to Close Stash Acquisition in 3Q of 2026 >GRAB

11. veebr 2026, 22:22 UTC

Tulu

Grab Holdings to Acquire U.S. Digital Financial Services Company Stash Financial >GRAB

11. veebr 2026, 22:22 UTC

Tulu

Grab Holdings Sees FY26 Adj Ebitda $700M to $720M >GRAB

11. veebr 2026, 22:19 UTC

Tulu

Grab Holdings Sees FY26 Rev $4.04B to $4.10B >GRAB

11. veebr 2026, 22:18 UTC

Tulu

Grab Holdings 4Q Adj Ebitda $148.0M Vs. $97.0M >GRAB

11. veebr 2026, 22:18 UTC

Tulu

Grab Holdings 4Q Net $153.0M Vs. Net $11.0M >GRAB

11. veebr 2026, 22:18 UTC

Tulu

Grab Holdings 4Q Oper Pft $52.0M Vs. $2.0M >GRAB

11. veebr 2026, 22:16 UTC

Tulu

Grab Holdings 4Q Rev $906.0M Vs. $764.0M >GRAB

Võrdlus sarnastega

Hinnamuutus

Gossamer Bio Inc Prognoos

Hinnasiht

By TipRanks

401.33% tõus

12 kuu keskmine prognoos

Keskmine 11.33 USD 401.33%

Kõrge 15 USD

Madal 9 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Gossamer Bio Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Gossamer Bio Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.06 / 1.23Toetus ja vastupanu

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

44 / 352 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.